ENvue Medical (FEED) Stock Overview
Through its subsidiaries, focuses on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, wound healing, and at-home administration without medical professional assistance. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
FEED Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
ENvue Medical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.83 |
| 52 Week High | US$17.40 |
| 52 Week Low | US$0.72 |
| Beta | 1.5 |
| 1 Month Change | -24.27% |
| 3 Month Change | -43.59% |
| 1 Year Change | -91.54% |
| 3 Year Change | -99.80% |
| 5 Year Change | -99.90% |
| Change since IPO | -99.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| FEED | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 4.9% | 0.02% | 0.5% |
| 1Y | -91.5% | -20.4% | 23.5% |
Return vs Industry: FEED underperformed the US Medical Equipment industry which returned -20.4% over the past year.
Return vs Market: FEED underperformed the US Market which returned 23.5% over the past year.
Price Volatility
| FEED volatility | |
|---|---|
| FEED Average Weekly Movement | 22.7% |
| Medical Equipment Industry Average Movement | 8.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: FEED's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: FEED's weekly volatility has decreased from 29% to 23% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 13 | Doron Besser | envuemed.com |
ENvue Medical, Inc., through its subsidiaries, focuses on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, wound healing, and at-home administration without medical professional assistance. Its product portfolio includes UroShield, an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The company also offers PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures.
ENvue Medical, Inc. Fundamentals Summary
| FEED fundamental statistics | |
|---|---|
| Market cap | US$5.05m |
| Earnings (TTM) | -US$37.52m |
| Revenue (TTM) | US$2.18m |
Is FEED overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FEED income statement (TTM) | |
|---|---|
| Revenue | US$2.18m |
| Cost of Revenue | US$2.45m |
| Gross Profit | -US$271.00k |
| Other Expenses | US$37.25m |
| Earnings | -US$37.52m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.16 |
| Gross Margin | -12.43% |
| Net Profit Margin | -1,720.50% |
| Debt/Equity Ratio | 3.4% |
How did FEED perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/15 13:22 |
| End of Day Share Price | 2026/06/12 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ENvue Medical, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.